# Cagrilintide and CagriSema: what amylin adds to semaglutide

Source: https://pepvault.app/guides/cagrilintide-and-cagrisema

Last updated: 2026-11-20

Use: © PepVault. Read and cite with a link. Copying, bulk scraping, rewriting or republishing is not permitted (https://pepvault.app/terms#content).

[Guides](https://pepvault.app/guides) [GLP-1s](https://pepvault.app/guides#glp1)

# Cagrilintide and CagriSema: what amylin adds to semaglutide

Reviewed November 2026 20 sources [Published by PepVault](https://pepvault.app/guides/how-we-research)

Cagrilintide is a weekly amylin drug, not a GLP-1. What it did alone, what it added to semaglutide in CagriSema's trials, the side effects and FDA status.

- **Last reviewed:** Nov 20, 2026
- **Sources:** 20
- **Questions:** 7
- **Compounds:** 4

## The short answer

Cagrilintide is a weekly, long-acting version of amylin, a fullness hormone the pancreas releases with insulin; it is not a GLP-1. On its own it cut weight by 6 to 12% in trials. Paired with semaglutide as CagriSema, it added about 6.6 points for people who stayed on treatment: 22.7% against 16.1% on semaglutide alone at 68 weeks. As of November 20, 2026, neither is FDA approved.

- Amylin is made with insulin and slows the stomach, holds down glucagon and brings fullness on sooner.
- Cagrilintide alone: 6.0% to 10.8% weight loss at 26 weeks, 11.8% at 68 weeks while on treatment.
- CagriSema beat semaglutide alone in REDEFINE 1 (22.7% against 16.1%) and REDEFINE 5 (18.4% against 11.9%); on blood sugar the gain is small.
- Not FDA approved as of November 20, 2026: filed December 18, 2025, with a US launch planned for early 2027 if approved.

Every number checked at its primary source · Nov 20, 2026 · [20 sources](https://pepvault.app/guides/cagrilintide-and-cagrisema#sources) · [How we research](https://pepvault.app/guides/how-we-research)

**Evidence:** Phase 2 and phase 3 randomized trials in people, all funded by Novo Nordisk; as of November 2026 CagriSema is under FDA review and cagrilintide alone is in phase 3, so neither has a label.

## What is amylin, and what does it do?

Amylin is a hormone made by the same pancreas cells that make insulin. The two are packed together and released together when you eat, and in type 1 and type 2 diabetes both fall[1](https://pepvault.app/guides/cagrilintide-and-cagrisema#source-1). After a meal amylin does three jobs: it slows how fast the stomach empties, it holds down glucagon (the hormone that pushes blood sugar up), and it acts on fullness, so people eat less[1](https://pepvault.app/guides/cagrilintide-and-cagrisema#source-1).

The first drug built on it was pramlintide (Symlin), approved by the FDA on March 16, 2005, as an add-on for people with diabetes who use mealtime insulin[1](https://pepvault.app/guides/cagrilintide-and-cagrisema#source-1) [2](https://pepvault.app/guides/cagrilintide-and-cagrisema#source-2). It is human amylin with three of its 37 amino acids swapped for proline[1](https://pepvault.app/guides/cagrilintide-and-cagrisema#source-1). Natural amylin tends to clump into fibers, which makes it a hard molecule to turn into a medicine[3](https://pepvault.app/guides/cagrilintide-and-cagrisema#source-3). Pramlintide lasts about 48 minutes in the body, so it is injected right before each main meal, up to three times a day[1](https://pepvault.app/guides/cagrilintide-and-cagrisema#source-1) [3](https://pepvault.app/guides/cagrilintide-and-cagrisema#source-3). Drugs@FDA now lists every Symlin product as discontinued[2](https://pepvault.app/guides/cagrilintide-and-cagrisema#source-2).

<!--promo-->

PepVault for iPhone

## Keep your protocol in PepVault

PepVault's weight log charts every weigh-in week by week, so you can read your own curve against the trial numbers above.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=guide-card-flow&mt=8)

7 days free on the yearly plan for new subscribers.

<!--/promo-->

## Is cagrilintide a GLP-1?

No. Cagrilintide is an amylin analogue: a lab-made amylin built to last. Novo Nordisk's chemists made the molecule stable and attached a fatty-acid chain to make it long-acting[3](https://pepvault.app/guides/cagrilintide-and-cagrisema#source-3). In people its half-life, the time for the blood level to halve, measured 159 to 195 hours, about a week, so it is a once-weekly shot[5](https://pepvault.app/guides/cagrilintide-and-cagrisema#source-5). Semaglutide's half-life in the same trial was 145 to 165 hours, which is why the two fit in one weekly dose, and cagrilintide did not change semaglutide's levels[5](https://pepvault.app/guides/cagrilintide-and-cagrisema#source-5).

It also reaches wider than pramlintide. Amylin receptors are built from the calcitonin receptor plus a partner protein. Pramlintide switches on amylin receptors only; cagrilintide switches on amylin receptors and the calcitonin receptor itself[4](https://pepvault.app/guides/cagrilintide-and-cagrisema#source-4). That was measured in lab cells, not people, and the paper cites earlier data that drugs with this wider reach may work better for weight[4](https://pepvault.app/guides/cagrilintide-and-cagrisema#source-4).

Try it

How Cagrilintide builds up

An estimate from a half-life of about 7 days, one dose a week for four weeks. The shape of the level, not a measurement.

[Try your own schedule](https://pepvault.app/tools/peptide-half-life-calculator) [Cagrilintide in the library](https://pepvault.app/peptides/cagrilintide)

## What did cagrilintide do on its own?

Its first large test was a phase 2 trial published in The Lancet in 2021: 906 adults with obesity or overweight and no diabetes, at 57 sites in ten countries, for 26 weeks[6](https://pepvault.app/guides/cagrilintide-and-cagrisema#source-6). They took weekly cagrilintide at one of five doses from 0.3 to 4.5 mg, daily liraglutide 3.0 mg (the GLP-1 drug in Saxenda), or placebo[6](https://pepvault.app/guides/cagrilintide-and-cagrisema#source-6).

Every dose beat placebo: weight fell 6.0% to 10.8% against 3.0%[6](https://pepvault.app/guides/cagrilintide-and-cagrisema#source-6). The top dose, 4.5 mg, also beat liraglutide, 10.8% against 9.0%[6](https://pepvault.app/guides/cagrilintide-and-cagrisema#source-6). Those numbers estimate the loss had everyone stayed on the drug; the paper found similar results counting everyone[6](https://pepvault.app/guides/cagrilintide-and-cagrisema#source-6).

The 68-week REDEFINE 1 trial then gave 302 people cagrilintide 2.4 mg alone, reached after 16 weeks of dose steps[7](https://pepvault.app/guides/cagrilintide-and-cagrisema#source-7) [18](https://pepvault.app/guides/cagrilintide-and-cagrisema#source-18). They lost 11.8% on treatment, against 2.3% on placebo[9](https://pepvault.app/guides/cagrilintide-and-cagrisema#source-9); Novo Nordisk's announcement adds 11.5% counting everyone, against 3.0%[8](https://pepvault.app/guides/cagrilintide-and-cagrisema#source-8). By Novo's count it was the arm where most people stayed at full dose: 82.5% were on 2.4 mg at week 68, against 70.2% on semaglutide alone[8](https://pepvault.app/guides/cagrilintide-and-cagrisema#source-8). On its own, then, cagrilintide landed above liraglutide and below semaglutide.

## With this guide

### Cagrilintide

- [Cagrilintide: the full reference](https://pepvault.app/peptides/cagrilintide)
- [Cagrilintide dose guide](https://pepvault.app/lab/dosage/cagrilintide)

### CagriSema

- [CagriSema: the full reference](https://pepvault.app/peptides/cagrisema)
- [CagriSema dose guide](https://pepvault.app/lab/dosage/cagrisema)

### Mixing charts

- [Cagrilintide 5 mg vial](https://pepvault.app/tools/reconstitution-calculator/cagrilintide-5mg)
- [Cagrilintide 10 mg vial](https://pepvault.app/tools/reconstitution-calculator/cagrilintide-10mg)
- [Semaglutide 2 mg vial](https://pepvault.app/tools/reconstitution-calculator/semaglutide-2mg)
- [Semaglutide 5 mg vial](https://pepvault.app/tools/reconstitution-calculator/semaglutide-5mg)
- [Semaglutide 10 mg vial](https://pepvault.app/tools/reconstitution-calculator/semaglutide-10mg)

### Studies

- [CagriSema: 30.3% hit both BMI and waist-to-height targets at 68 weeks](https://pepvault.app/research/cagrilintide-redefine-1-2026)
- [CagriSema: 18.4% weight loss vs 11.9% on semaglutide in REDEFINE 5](https://pepvault.app/research/cagrisema-redefine-5-2026)
- [CagriSema: HbA1c down 2.33% at 40 weeks in REIMAGINE 3](https://pepvault.app/research/cagrisema-reimagine-3-2026)
- [All 7 studies](https://pepvault.app/research#cagrilintide)
- [All 4 studies](https://pepvault.app/research#cagrisema)

### Compared with

- [Cagrilintide vs Semaglutide](https://pepvault.app/peptides/compare/cagrilintide-vs-semaglutide)
- [Retatrutide vs Cagrilintide](https://pepvault.app/peptides/compare/retatrutide-vs-cagrilintide)
- [Tirzepatide vs Cagrilintide](https://pepvault.app/peptides/compare/tirzepatide-vs-cagrilintide)
- [Cagrilintide vs Pramlintide](https://pepvault.app/peptides/compare/cagrilintide-vs-pramlintide)
- [Cagrilintide vs Eloralintide](https://pepvault.app/peptides/compare/cagrilintide-vs-eloralintide)
- [Cagrilintide vs Petrelintide](https://pepvault.app/peptides/compare/cagrilintide-vs-petrelintide)

### Tools

- [Reconstitution calculator](https://pepvault.app/tools/reconstitution-calculator)
- [How long will my vial last?](https://pepvault.app/tools/how-long-will-my-vial-last)
- [Is my mixed vial still good?](https://pepvault.app/tools/reconstituted-peptide-expiry)
- [Half-life calculator](https://pepvault.app/tools/peptide-half-life-calculator)

### The GLP-1 path

- [Retatrutide week by week](https://pepvault.app/guides/retatrutide-week-by-week)
- [Retatrutide dosage: the trial step-ups](https://pepvault.app/guides/retatrutide-dosage-in-trials)
- [Tirzepatide week by week](https://pepvault.app/guides/tirzepatide-week-by-week)
- [Semaglutide week by week](https://pepvault.app/guides/semaglutide-week-by-week)
- [Tirzepatide dosage: every step from 2.5 to 15 mg (Mounjaro and Zepbound)](https://pepvault.app/guides/tirzepatide-dosage)
- [Wegovy and Ozempic dosage: both labels' steps in one table, and why the two differ](https://pepvault.app/guides/wegovy-and-ozempic-dosage)
- [How to use the Zepbound KwikPen](https://pepvault.app/guides/how-to-use-the-zepbound-kwikpen)
- [How to use the Ozempic and Wegovy pens: needles, the dose counter and clicks](https://pepvault.app/guides/how-to-use-ozempic-and-wegovy-pens)
- [What time of day to take your GLP-1 shot or pill, and can you change the day?](https://pepvault.app/guides/when-to-take-your-glp-1)
- [Switching GLP-1s: Ozempic to Zepbound, shot to pill, and what the trials tested](https://pepvault.app/guides/switching-between-glp-1s)
- [Ozempic vs Wegovy vs Mounjaro vs Zepbound: the four labels in one table](https://pepvault.app/guides/ozempic-wegovy-mounjaro-zepbound)
- [Is Ozempic insulin? GLP-1, GIP and insulin explained](https://pepvault.app/guides/is-ozempic-insulin)
- [The Wegovy pill: what it is, how its label differs from the shot, and the trial numbers](https://pepvault.app/guides/the-wegovy-pill)
- [Ozempic and Wegovy side effects: what the trials counted and when they showed up](https://pepvault.app/guides/ozempic-and-wegovy-side-effects)
- [Semaglutide vs tirzepatide side effects: what the head-to-head trials found](https://pepvault.app/guides/sema-vs-tirzepatide-side-effects)
- [Microdosing a GLP-1: what it means and what has been tested](https://pepvault.app/guides/microdosing-a-glp-1)
- [GLP-1s and sleep apnea: Zepbound's OSA approval](https://pepvault.app/guides/glp-1-and-sleep-apnea)
- [Retatrutide first dose: the first four weeks in the trials](https://pepvault.app/guides/retatrutide-first-dose)
- [Retatrutide side effects: what the trials counted](https://pepvault.app/guides/retatrutide-side-effects)
- [Retatrutide not working? Stalls, slow responders and the plateau](https://pepvault.app/guides/retatrutide-not-working)
- [Switching from tirzepatide to retatrutide: what is known](https://pepvault.app/guides/tirzepatide-to-retatrutide)
- [Is retatrutide safe? What the trials reported](https://pepvault.app/guides/is-retatrutide-safe)
- [When will retatrutide be approved?](https://pepvault.app/guides/when-will-retatrutide-be-approved)
- [TRIUMPH-5 results: retatrutide vs tirzepatide head to head](https://pepvault.app/guides/triumph-5-results)
- [CagriSema FDA approval: when it's due, the dose filed, and what the trials showed](https://pepvault.app/guides/cagrisema-fda-decision)
- [MariTide phase 3 results (MARITIME-1): what to expect](https://pepvault.app/guides/maritime-1-results)
- [Aleniglipron: the GLP-1 pill, and the trial switching people from shots to it](https://pepvault.app/guides/aleniglipron-switch-trial)
- [Mounjaro and Zepbound side effects by dose: the rates at each step](https://pepvault.app/guides/mounjaro-zepbound-side-effects)
- [Hair loss on a GLP-1: how common it is per drug, and why](https://pepvault.app/guides/hair-loss-on-a-glp-1)
- ["Ozempic face": what it is, and where the weight comes from](https://pepvault.app/guides/ozempic-face)
- [Foundayo (orforglipron) vs the shots: the trial numbers side by side](https://pepvault.app/guides/foundayo-vs-the-shots)
- [Is compounded semaglutide or tirzepatide the same as Ozempic or Zepbound?](https://pepvault.app/guides/compounded-glp-1-vs-brand)
- [Why compounded semaglutide and tirzepatide come with B12, glycine or B6, and what it changes](https://pepvault.app/guides/compounded-glp-1-with-b12)
- [Is there a generic Ozempic? Generic semaglutide and Sevmia](https://pepvault.app/guides/generic-semaglutide)
- [How much does a GLP-1 cost in 2026? Zepbound, Wegovy and Medicare prices](https://pepvault.app/guides/how-much-does-a-glp-1-cost)
- [What to eat on a GLP-1: what the trials and the guidelines say](https://pepvault.app/guides/what-to-eat-on-a-glp-1)
- [How much protein per day? The numbers by weight and goal](https://pepvault.app/guides/how-much-protein-per-day)
- [Muscle on a GLP-1: how much of the weight lost is lean mass?](https://pepvault.app/guides/muscle-on-a-glp-1)
- [Intermittent fasting on a GLP-1: what the trials and labels say](https://pepvault.app/guides/intermittent-fasting-on-a-glp-1)
- [Coffee on a GLP-1: can you drink it, and why it can taste different](https://pepvault.app/guides/coffee-on-a-glp-1)
- [Food noise on a GLP-1: what it is and what happens after stopping](https://pepvault.app/guides/food-noise-on-a-glp-1)
- [GLP-1s and menopause: what the trials say about women in midlife](https://pepvault.app/guides/glp-1s-and-menopause)
- [Stopping a GLP-1: what happens to your weight](https://pepvault.app/guides/stopping-a-glp-1)
- [How to keep the weight off after a GLP-1: what each trial tested](https://pepvault.app/guides/keeping-weight-off-after-a-glp-1)
- [Berberine vs metformin vs a GLP-1: what each does to weight and glucose](https://pepvault.app/guides/berberine-vs-metformin-vs-glp-1)
- [Natural GLP-1 alternatives: what the evidence shows for berberine, fiber and supplements](https://pepvault.app/guides/natural-glp-1-alternatives)
- [What is 5-Amino-1MQ? What's been measured](https://pepvault.app/guides/5-amino-1mq-explained)
- [Retatrutide from a lab vial: what independent testing found](https://pepvault.app/guides/retatrutide-lab-vial-tests)
- [Switching from Saxenda to Wegovy: how the change works](https://pepvault.app/guides/saxenda-to-wegovy)
- [Do you stop Ozempic, Wegovy, Mounjaro or Zepbound before surgery?](https://pepvault.app/guides/glp-1-before-surgery)
- [Diarrhea on a GLP-1: how common, and how long it lasts](https://pepvault.app/guides/diarrhea-on-a-glp-1)
- [Dizziness on a GLP-1: dehydration, blood pressure or blood sugar?](https://pepvault.app/guides/dizziness-on-a-glp-1)
- [Heartburn and acid reflux on a GLP-1: the rates, the timing and what helps](https://pepvault.app/guides/heartburn-on-a-glp-1)
- [Does Ozempic or Mounjaro make you tired? Fatigue in the trials](https://pepvault.app/guides/glp-1-fatigue)
- [Can a GLP-1 cause low blood sugar if you do not have diabetes?](https://pepvault.app/guides/glp-1-low-blood-sugar)
- [Is there a medicine for GLP-1 nausea? Tradipitant, so far](https://pepvault.app/guides/tradipitant-for-glp-1-nausea)
- [GLP-1s and mood: depression, anxiety and what the FDA review found](https://pepvault.app/guides/glp-1s-and-mood)
- [Can Ozempic cause vision loss? GLP-1s and NAION, by the numbers](https://pepvault.app/guides/glp-1-and-naion)
- [Are GLP-1s safe long term? What the longest trials show](https://pepvault.app/guides/are-glp-1s-safe-long-term)
- [GLP-1s and the kidneys: what FLOW showed, and the dehydration risk](https://pepvault.app/guides/glp-1s-and-the-kidneys)
- [Can you drink alcohol on Ozempic, Mounjaro or another GLP-1?](https://pepvault.app/guides/alcohol-on-a-glp-1)
- [Do GLP-1s reduce alcohol cravings? What the trials found](https://pepvault.app/guides/glp-1-and-alcohol-cravings)
- [GLP-1s and fatty liver: what the trials measured](https://pepvault.app/guides/glp-1-and-fatty-liver)
- [GLP-1s after a gastric sleeve or bypass: regain, dosing and sleeve vs GLP-1](https://pepvault.app/guides/glp-1-after-bariatric-surgery)
- [Can you drink alcohol on retatrutide?](https://pepvault.app/guides/retatrutide-and-alcohol)
- [Ozempic, Wegovy, Mounjaro or Zepbound not working? Slow responders and plateaus in the trials](https://pepvault.app/guides/glp-1-not-working)
- [Intermittent fasting for weight and fat loss: what the trials measured](https://pepvault.app/guides/intermittent-fasting-weight-loss)
- [Can you take metformin with Ozempic, Mounjaro or another GLP-1?](https://pepvault.app/guides/metformin-with-a-glp-1)
- [GLP-1s and pregnancy: Ozempic, Wegovy, Mounjaro and Zepbound before and during](https://pepvault.app/guides/glp-1s-and-pregnancy)
- [Can you take Ozempic, Mounjaro or another GLP-1 while breastfeeding?](https://pepvault.app/guides/glp-1-while-breastfeeding)
- [Eloralintide, petrelintide and amycretin: the amylin drugs in trials](https://pepvault.app/guides/amylin-drugs-in-trials)
- [Olatorepatide (HS-20094): Regeneron's obesity drug, what is known so far](https://pepvault.app/guides/olatorepatide-explained)
- [Berobenatide (PF-08653944, MET-097i): Pfizer's monthly GLP-1 shot, what is known so far](https://pepvault.app/guides/berobenatide-explained)
- [The GLP-1 pipeline: every drug in phase 2 and 3, and when its trials finish](https://pepvault.app/guides/glp-1-pipeline)
- [Is there a monthly GLP-1 shot? MariTide and berobenatide](https://pepvault.app/guides/monthly-glp-1-shots)
- [Cagrilintide alone: RENEW 1 phase 3 results and what to expect](https://pepvault.app/guides/renew-1-cagrilintide-results)
- [Wegovy HD: is 7.2 mg worth it, and what changes from 2.4 mg](https://pepvault.app/guides/wegovy-hd-7-2-mg)
- [Zenagamtide (amycretin): Novo's GLP-1 and amylin shot and pill, what the trials show](https://pepvault.app/guides/zenagamtide-amycretin)
- [Wegovy and Ozempic price, Medicare and WADA: what changes on January 1, 2027](https://pepvault.app/guides/glp-1-changes-january-2027)
- [Can you take sermorelin with Ozempic, Mounjaro or another GLP-1?](https://pepvault.app/guides/sermorelin-with-a-glp-1)
- [Retatrutide in women: what the studies included](https://pepvault.app/guides/retatrutide-in-women)
- [Peptides for women: what the trials in women show, and after 40](https://pepvault.app/guides/peptides-for-women)
- [Low-dose naltrexone (LDN) for weight loss: what the trials measured](https://pepvault.app/guides/ldn-for-weight-loss)
- [GLP-1s and PCOS: what the trials show, and how they compare with metformin](https://pepvault.app/guides/glp-1-and-pcos)
- [GLP-1s and sleep: insomnia, vivid dreams and the sleep apnea approval](https://pepvault.app/guides/glp-1s-and-sleep)

### Terms on this page

- [Amino acid](https://pepvault.app/glossary/amino-acid)
- [Half-life](https://pepvault.app/glossary/half-life)
- [GLP-1](https://pepvault.app/glossary/glp-1)
- [Glucagon](https://pepvault.app/glossary/glucagon)
- [Placebo](https://pepvault.app/glossary/placebo)
- [Boxed warning](https://pepvault.app/glossary/boxed-warning)
- [Discontinued (Drugs@FDA)](https://pepvault.app/glossary/discontinued)
- [Double-blind](https://pepvault.app/glossary/double-blind)

## How much does amylin add to semaglutide?

REDEFINE 1 was built to show it. It gave 3,417 adults without diabetes the pair (CagriSema, 2.4 mg of each), semaglutide 2.4 mg alone, cagrilintide 2.4 mg alone or placebo for 68 weeks, in a ratio of 21:3:3:7[7](https://pepvault.app/guides/cagrilintide-and-cagrisema#source-7). Its main test was the pair against placebo; the single-drug arms show what each half brings[7](https://pepvault.app/guides/cagrilintide-and-cagrisema#source-7) [8](https://pepvault.app/guides/cagrilintide-and-cagrisema#source-8).

Trials count weight loss two ways. **On treatment** estimates the loss had everyone stayed on the drug. **Everyone** counts every person randomized, including those who stopped, so it runs a little lower. Each row below is one trial; compare the columns within a row, not rows with each other, because the trials differ in who took part, how long they ran and how they counted.

| Trial (who, length, how counted) | CagriSema | Semaglutide alone | Cagrilintide alone | Placebo |
| --- | --- | --- | --- | --- |
| REDEFINE 1, no diabetes, 68 weeks, on treatment[8](https://pepvault.app/guides/cagrilintide-and-cagrisema#source-8) [9](https://pepvault.app/guides/cagrilintide-and-cagrisema#source-9) | −22.7% | −16.1% | −11.8% | −2.3% |
| REDEFINE 1, the same trial, everyone; single-drug arms from Novo[7](https://pepvault.app/guides/cagrilintide-and-cagrisema#source-7) [8](https://pepvault.app/guides/cagrilintide-and-cagrisema#source-8) | −20.4% | −14.9% | −11.5% | −3.0% |
| REDEFINE 5, Japan and Taiwan, 68 weeks, on treatment[11](https://pepvault.app/guides/cagrilintide-and-cagrisema#source-11) | −18.4% | −11.9% | Not in trial | Not in trial |
| REDEFINE 2, type 2 diabetes, 68 weeks, everyone[10](https://pepvault.app/guides/cagrilintide-and-cagrisema#source-10) | −13.7% | Not in trial | Not in trial | −3.4% |
| REDEFINE 9, 1.0 or 1.7 mg of each, 68 weeks, on treatment[13](https://pepvault.app/guides/cagrilintide-and-cagrisema#source-13) | −21.0% (1.0 mg), −20.7% (1.7 mg) | Not in trial | Not in trial | −2.0% |
| Phase 2, 92 people with type 2 diabetes, 32 weeks[12](https://pepvault.app/guides/cagrilintide-and-cagrisema#source-12) | −15.6% | −5.1% | −8.1% | Not in trial |
| Phase 2, cagrilintide alone, 26 weeks, on treatment[6](https://pepvault.app/guides/cagrilintide-and-cagrisema#source-6) | Not in trial | Not in trial | −6.0% to −10.8% | −3.0% |

Read REDEFINE 1 across: amylin added 6.6 percentage points to semaglutide on treatment (22.7% against 16.1%)[9](https://pepvault.app/guides/cagrilintide-and-cagrisema#source-9), and 5.5 points counting everyone (20.4% against 14.9%) by Novo's figures[8](https://pepvault.app/guides/cagrilintide-and-cagrisema#source-8). Novo's announcement puts the biggest change at the deep end: 40.4% on the pair lost a quarter or more of their body weight, against 16.2% on semaglutide alone and 6.0% on cagrilintide alone[8](https://pepvault.app/guides/cagrilintide-and-cagrisema#source-8). The pair did this with fewer people at full dose. REDEFINE 1 let people stay on a lower step, and only 57.3% on CagriSema were on 2.4 mg of each at the end[8](https://pepvault.app/guides/cagrilintide-and-cagrisema#source-8).

REDEFINE 5 made the pair against semaglutide its main question, double-blind, and the gap held at 6.5 percentage points[11](https://pepvault.app/guides/cagrilintide-and-cagrisema#source-11). In a separate trial, REDEFINE 9, the lower doses of 1.0 mg and 1.7 mg of each brought about 21% on treatment at 68 weeks[13](https://pepvault.app/guides/cagrilintide-and-cagrisema#source-13). How the pair compares with tirzepatide (Zepbound) is its own guide.

On blood sugar, amylin adds less. In REIMAGINE 2, 2,713 adults with type 2 diabetes, double-blind for 68 weeks, HbA1c (the three-month blood sugar average) fell 1.91 points on the pair against 1.75 on semaglutide alone, a small but real gap[20](https://pepvault.app/guides/cagrilintide-and-cagrisema#source-20). In the 32-week phase 2 trial the gap, 2.2 against 1.8 points, was too small to be sure of[12](https://pepvault.app/guides/cagrilintide-and-cagrisema#source-12).

<!--promo-->

PepVault's weight log charts every weigh-in week by week, so you can read your own curve against the trial numbers above. [Track your weight in PepVault](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=guide-cagrilintide-and-cagrisema-inline&mt=8)

<!--/promo-->

## What side effects does CagriSema cause?

Mostly stomach effects, mostly early, mostly mild to moderate. In REDEFINE 1, 79.6% on the pair had a stomach or gut side effect at some point in the 68 weeks, against 39.9% on placebo, and most passed[7](https://pepvault.app/guides/cagrilintide-and-cagrisema#source-7); nausea led the list at 55% (12.6% on placebo), and 5.9% stopped over side effects, against 3.5%[14](https://pepvault.app/guides/cagrilintide-and-cagrisema#source-14).

Against semaglutide alone, amylin added little to the stomach load. In REDEFINE 5, 53% on the pair and 51% on semaglutide had a gut side effect, and 10% and 6% stopped treatment for any reason[11](https://pepvault.app/guides/cagrilintide-and-cagrisema#source-11). Cagrilintide alone, in its phase 2 trial, brought gut side effects to 41% to 63% across doses against 32% on placebo, mainly nausea (20% to 47% against 18%), with injection-site reactions among the most frequent events[6](https://pepvault.app/guides/cagrilintide-and-cagrisema#source-6).

**Commonly reported:** feeling full a few bites into a meal and portions shrinking without effort, with nausea or constipation in the days after a dose step that eases once the dose holds.

CagriSema has no label yet. Its semaglutide half carries Wegovy's warnings, including a boxed warning for thyroid C-cell tumors seen in rodents and a rule against use with a personal or family history of medullary thyroid cancer or MEN 2[17](https://pepvault.app/guides/cagrilintide-and-cagrisema#source-17).

**When to get help** Stomach pain that is severe or will not go away, sometimes reaching through to the back, with or without vomiting, is the semaglutide label's sign of possible pancreatitis and a reason to contact your clinician promptly[17](https://pepvault.app/guides/cagrilintide-and-cagrisema#source-17).

<!--promo-->

PepVault logs side effects by day next to your dose log, so you can see whether nausea settles after a step-up. [Log it in PepVault](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=guide-cagrilintide-and-cagrisema-inline&mt=8)

<!--/promo-->

## Is cagrilintide or CagriSema FDA approved?

Not as of November 20, 2026. Drugs@FDA has no product containing cagrilintide[19](https://pepvault.app/guides/cagrilintide-and-cagrisema#source-19). Novo Nordisk submitted CagriSema (2.4 mg of each, once weekly) to the FDA on December 18, 2025, for weight loss in adults with obesity, or with overweight and at least one weight-related condition[14](https://pepvault.app/guides/cagrilintide-and-cagrisema#source-14). Its November 4, 2026 report puts the US decision in the fourth quarter of 2026 and says Novo is "preparing for the US launch of CagriSema in early 2027, subject to regulatory approval"[15](https://pepvault.app/guides/cagrilintide-and-cagrisema#source-15). Our CagriSema decision guide follows the review clock.

Cagrilintide on its own is a step behind. Its own phase 3 program, RENEW, is running: RENEW 1 gives about 300 adults with overweight or obesity weekly cagrilintide or placebo for 64 weeks[16](https://pepvault.app/guides/cagrilintide-and-cagrisema#source-16). The registry estimates its primary completion for May 2027, and Novo's milestone table puts RENEW 1 and 2 results in the second half of 2027[15](https://pepvault.app/guides/cagrilintide-and-cagrisema#source-15) [16](https://pepvault.app/guides/cagrilintide-and-cagrisema#source-16). Until a label exists, every dose quoted for either drug is a trial dose: REDEFINE 1 reached 2.4 mg after 16 weeks of steps, and the phase 2 trial tested 0.3 to 4.5 mg[6](https://pepvault.app/guides/cagrilintide-and-cagrisema#source-6) [18](https://pepvault.app/guides/cagrilintide-and-cagrisema#source-18).

<!--promo-->

CagriSema and cagrilintide are in PepVault's library: set the weekly shot day once, get a reminder each week, and every dose you log stays in your history. [Set reminders in PepVault](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=guide-cagrilintide-and-cagrisema-inline&mt=8)

<!--/promo-->

## What other amylin drugs are in trials?

Cagrilintide is not the only long-acting amylin drug. Eloralintide, petrelintide and amycretin are the next wave, each built differently, and all are still in trials. Cagrilintide's own phase 3 readout, RENEW 1, has a guide of its own.

<!--promo-->

[Track it in the app](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=guide-card-next&mt=8)

<!--/promo-->

## Sources

1. Symlin (pramlintide acetate) prescribing information, AstraZeneca. DailyMed, SPL version 18, effective December 18, 2019. [dailymed.nlm.nih.gov](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4aea30ff-eb0d-45c1-b114-3127966328ff)
2. Drugs@FDA: NDA 021332, Symlin (pramlintide acetate); original approval March 16, 2005; all products listed as discontinued (read November 20, 2026). [accessdata.fda.gov](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021332)
3. Kruse T et al. Development of cagrilintide, a long-acting amylin analogue. J Med Chem. 2021;64(15):11183-11194. [PubMed 34288673](https://pubmed.ncbi.nlm.nih.gov/34288673/)
4. Fletcher MM et al. AM833 is a novel agonist of calcitonin family G protein-coupled receptors. J Pharmacol Exp Ther. 2021;377(3):417-440. [PubMed 33727283](https://pubmed.ncbi.nlm.nih.gov/33727283/)
5. Enebo LB et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2.4 mg for weight management: a randomised, controlled, phase 1b trial. Lancet. 2021;397:1736-1748. [PubMed 33894838](https://pubmed.ncbi.nlm.nih.gov/33894838/)
6. Lau DCW et al. Once-weekly cagrilintide for weight management in people with overweight and obesity: a dose-finding phase 2 trial. Lancet. 2021;398(10317):2160-2172. [PubMed 34798060](https://pubmed.ncbi.nlm.nih.gov/34798060/)
7. Garvey WT et al. Coadministered cagrilintide and semaglutide in adults with overweight or obesity (REDEFINE 1). N Engl J Med. 2025;393(7):635-647. [PubMed 40544433](https://pubmed.ncbi.nlm.nih.gov/40544433/)
8. Novo Nordisk company announcement No 99/2024: CagriSema demonstrates superior weight loss in adults with obesity or overweight in the REDEFINE 1 trial. December 20, 2024 (Form 6-K, SEC EDGAR). [sec.gov](https://www.sec.gov/Archives/edgar/data/353278/000117184324007023/f6k_122024.htm)
9. Busetto L et al. Efficacy of CagriSema for reaching anthropometric treatment targets and cardiometabolic outcomes: a secondary, post hoc analysis of REDEFINE 1. Diabetes Obes Metab. 2026;28(10):9317-9325. [PubMed 42503495](https://pubmed.ncbi.nlm.nih.gov/42503495/)
10. Davies MJ et al. Cagrilintide-semaglutide in adults with overweight or obesity and type 2 diabetes (REDEFINE 2). N Engl J Med. 2025;393(7):648-659. [PubMed 40544432](https://pubmed.ncbi.nlm.nih.gov/40544432/)
11. Yamauchi T et al. Co-administered cagrilintide and semaglutide versus semaglutide alone in adults in Japan and Taiwan (REDEFINE 5): a phase 3a trial. Lancet Diabetes Endocrinol. 2026;14(6):450-462. [PubMed 42009015](https://pubmed.ncbi.nlm.nih.gov/42009015/)
12. Frias JP et al. Efficacy and safety of co-administered once-weekly cagrilintide 2.4 mg with once-weekly semaglutide 2.4 mg in type 2 diabetes: a phase 2 trial. Lancet. 2023;402(10403):720-730. [PubMed 37364590](https://pubmed.ncbi.nlm.nih.gov/37364590/)
13. Wharton S et al. Co-administered cagrilintide-semaglutide 1.7 mg each and 1.0 mg each in adults with overweight or obesity (REDEFINE 9): a phase 3b trial. Lancet Diabetes Endocrinol. Published online November 14, 2026. [PubMed 43033821](https://pubmed.ncbi.nlm.nih.gov/43033821/)
14. Novo Nordisk: CagriSema submitted to the US FDA for weight management. Company announcement, December 18, 2025. [novonordisk.com](https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=916470)
15. Novo Nordisk financial report for the first nine months of 2026. November 4, 2026 (Form 6-K, SEC EDGAR). [sec.gov](https://www.sec.gov/Archives/edgar/data/353278/000162828026069805/caq32026.htm)
16. ClinicalTrials.gov NCT07220642 (RENEW 1): Efficacy and safety of cagrilintide for weight management in participants with overweight or obesity. Novo Nordisk (read November 20, 2026). [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07220642)
17. Wegovy (semaglutide) prescribing information, Novo Nordisk. DailyMed, SPL version 19, effective June 18, 2026. [dailymed.nlm.nih.gov](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b)
18. ClinicalTrials.gov NCT05567796 (REDEFINE 1): arms and dose-escalation period. Novo Nordisk (read November 20, 2026). [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05567796)
19. openFDA Drugs@FDA query for the active ingredient cagrilintide: no matches (read November 20, 2026). [api.fda.gov](https://api.fda.gov/drug/drugsfda.json?search=products.active_ingredients.name:CAGRILINTIDE)
20. Buse JB et al. Cagrilintide-semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2): a double-blind, randomised, controlled, phase 3 study. Lancet Diabetes Endocrinol. 2026;14(8):662-677. [PubMed 42251859](https://pubmed.ncbi.nlm.nih.gov/42251859/)

<!--promo-->

Newsletter · Weekly

## The weekly peptide briefing.

New guides, the week’s peptide news, one tool. Free, one email a week, unsubscribe anytime.

<!--/promo-->

## Next guide · GLP-1

Guide · GLP-1

### [Berobenatide (PF-08653944, MET-097i): Pfizer's monthly GLP-1 shot, what is known so far](https://pepvault.app/guides/berobenatide-explained)

Berobenatide (PF-08653944, MET-097i) is Pfizer's monthly GLP-1 shot in phase 3: how it lasts, every phase 2 number, all 24 trials, and when results are due.

Read the next guide

<!--promo-->

PepVault for iPhone

## Keep your protocol in PepVault

Log every dose, track every vial, and see your protocol come together.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=guide-card-end&mt=8)

7 days free on the yearly plan for new subscribers.

[Explore the live demo](https://pepvault.app/login)

<!--/promo-->

## In the library

- [Cagrilintide Studied range: 0.25–2.4 mg](https://pepvault.app/peptides/cagrilintide)
- [CagriSema Studied range: 0.25–2.4 mg](https://pepvault.app/peptides/cagrisema)
- [Pramlintide Studied range: 15–120 mcg](https://pepvault.app/peptides/pramlintide)
- [Semaglutide Studied range: 0.25–2.4 mg](https://pepvault.app/peptides/semaglutide)

## Related guides

- Guide · GLP-1s

  ### [CagriSema FDA approval: when it's due, the dose filed, and what the trials showed](https://pepvault.app/guides/cagrisema-fda-decision)

  CagriSema is not FDA approved yet (Nov 20, 2026); Novo expects a decision in Q4 2026. The dose it filed, the warnings to expect and five trials' numbers.

  Read the guide
- Guide · GLP-1s

  ### [Cagrilintide alone: RENEW 1 phase 3 results and what to expect](https://pepvault.app/guides/renew-1-cagrilintide-results)

  Cagrilintide alone in phase 3: what RENEW 1, 2 and 4 test, the 11.8% bar REDEFINE 1 set, how it compares with semaglutide, and when results are due.

  Read the guide
- Guide · GLP-1s

  ### [Semaglutide week by week](https://pepvault.app/guides/semaglutide-week-by-week)

  What to expect on semaglutide week by week: the Wegovy label's dose steps, what the STEP trials saw at each stage, appetite, side effects and the plateau.

  Read the guide

## Guides

- [All guides](https://pepvault.app/guides)
- [How we research](https://pepvault.app/guides/how-we-research)

<!--promo-->

PepVault for iPhone

## Keep your protocol in PepVault

Log every dose, track every vial, and see your protocol come together.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=guide-card-rail&mt=8)

7 days free on the yearly plan for new subscribers.

<!--/promo-->

## With this guide

### Cagrilintide

- [Cagrilintide: the full reference](https://pepvault.app/peptides/cagrilintide)
- [Cagrilintide dose guide](https://pepvault.app/lab/dosage/cagrilintide)

### CagriSema

- [CagriSema: the full reference](https://pepvault.app/peptides/cagrisema)
- [CagriSema dose guide](https://pepvault.app/lab/dosage/cagrisema)

### Mixing charts

- [Cagrilintide 5 mg vial](https://pepvault.app/tools/reconstitution-calculator/cagrilintide-5mg)
- [Cagrilintide 10 mg vial](https://pepvault.app/tools/reconstitution-calculator/cagrilintide-10mg)
- [Semaglutide 2 mg vial](https://pepvault.app/tools/reconstitution-calculator/semaglutide-2mg)
- [Semaglutide 5 mg vial](https://pepvault.app/tools/reconstitution-calculator/semaglutide-5mg)
- [Semaglutide 10 mg vial](https://pepvault.app/tools/reconstitution-calculator/semaglutide-10mg)

### Studies

- [CagriSema: 30.3% hit both BMI and waist-to-height targets at 68 weeks](https://pepvault.app/research/cagrilintide-redefine-1-2026)
- [CagriSema: 18.4% weight loss vs 11.9% on semaglutide in REDEFINE 5](https://pepvault.app/research/cagrisema-redefine-5-2026)
- [CagriSema: HbA1c down 2.33% at 40 weeks in REIMAGINE 3](https://pepvault.app/research/cagrisema-reimagine-3-2026)
- [All 7 studies](https://pepvault.app/research#cagrilintide)
- [All 4 studies](https://pepvault.app/research#cagrisema)

### Compared with

- [Cagrilintide vs Semaglutide](https://pepvault.app/peptides/compare/cagrilintide-vs-semaglutide)
- [Retatrutide vs Cagrilintide](https://pepvault.app/peptides/compare/retatrutide-vs-cagrilintide)
- [Tirzepatide vs Cagrilintide](https://pepvault.app/peptides/compare/tirzepatide-vs-cagrilintide)
- [Cagrilintide vs Pramlintide](https://pepvault.app/peptides/compare/cagrilintide-vs-pramlintide)
- [Cagrilintide vs Eloralintide](https://pepvault.app/peptides/compare/cagrilintide-vs-eloralintide)
- [Cagrilintide vs Petrelintide](https://pepvault.app/peptides/compare/cagrilintide-vs-petrelintide)

### Tools

- [Reconstitution calculator](https://pepvault.app/tools/reconstitution-calculator)
- [How long will my vial last?](https://pepvault.app/tools/how-long-will-my-vial-last)
- [Is my mixed vial still good?](https://pepvault.app/tools/reconstituted-peptide-expiry)
- [Half-life calculator](https://pepvault.app/tools/peptide-half-life-calculator)

### The GLP-1 path

- [Retatrutide week by week](https://pepvault.app/guides/retatrutide-week-by-week)
- [Retatrutide dosage: the trial step-ups](https://pepvault.app/guides/retatrutide-dosage-in-trials)
- [Tirzepatide week by week](https://pepvault.app/guides/tirzepatide-week-by-week)
- [Semaglutide week by week](https://pepvault.app/guides/semaglutide-week-by-week)
- [Tirzepatide dosage: every step from 2.5 to 15 mg (Mounjaro and Zepbound)](https://pepvault.app/guides/tirzepatide-dosage)
- [Wegovy and Ozempic dosage: both labels' steps in one table, and why the two differ](https://pepvault.app/guides/wegovy-and-ozempic-dosage)
- [How to use the Zepbound KwikPen](https://pepvault.app/guides/how-to-use-the-zepbound-kwikpen)
- [How to use the Ozempic and Wegovy pens: needles, the dose counter and clicks](https://pepvault.app/guides/how-to-use-ozempic-and-wegovy-pens)
- [What time of day to take your GLP-1 shot or pill, and can you change the day?](https://pepvault.app/guides/when-to-take-your-glp-1)
- [Switching GLP-1s: Ozempic to Zepbound, shot to pill, and what the trials tested](https://pepvault.app/guides/switching-between-glp-1s)
- [Ozempic vs Wegovy vs Mounjaro vs Zepbound: the four labels in one table](https://pepvault.app/guides/ozempic-wegovy-mounjaro-zepbound)
- [Is Ozempic insulin? GLP-1, GIP and insulin explained](https://pepvault.app/guides/is-ozempic-insulin)
- [The Wegovy pill: what it is, how its label differs from the shot, and the trial numbers](https://pepvault.app/guides/the-wegovy-pill)
- [Ozempic and Wegovy side effects: what the trials counted and when they showed up](https://pepvault.app/guides/ozempic-and-wegovy-side-effects)
- [Semaglutide vs tirzepatide side effects: what the head-to-head trials found](https://pepvault.app/guides/sema-vs-tirzepatide-side-effects)
- [Microdosing a GLP-1: what it means and what has been tested](https://pepvault.app/guides/microdosing-a-glp-1)
- [GLP-1s and sleep apnea: Zepbound's OSA approval](https://pepvault.app/guides/glp-1-and-sleep-apnea)
- [Retatrutide first dose: the first four weeks in the trials](https://pepvault.app/guides/retatrutide-first-dose)
- [Retatrutide side effects: what the trials counted](https://pepvault.app/guides/retatrutide-side-effects)
- [Retatrutide not working? Stalls, slow responders and the plateau](https://pepvault.app/guides/retatrutide-not-working)
- [Switching from tirzepatide to retatrutide: what is known](https://pepvault.app/guides/tirzepatide-to-retatrutide)
- [Is retatrutide safe? What the trials reported](https://pepvault.app/guides/is-retatrutide-safe)
- [When will retatrutide be approved?](https://pepvault.app/guides/when-will-retatrutide-be-approved)
- [TRIUMPH-5 results: retatrutide vs tirzepatide head to head](https://pepvault.app/guides/triumph-5-results)
- [CagriSema FDA approval: when it's due, the dose filed, and what the trials showed](https://pepvault.app/guides/cagrisema-fda-decision)
- [MariTide phase 3 results (MARITIME-1): what to expect](https://pepvault.app/guides/maritime-1-results)
- [Aleniglipron: the GLP-1 pill, and the trial switching people from shots to it](https://pepvault.app/guides/aleniglipron-switch-trial)
- [Mounjaro and Zepbound side effects by dose: the rates at each step](https://pepvault.app/guides/mounjaro-zepbound-side-effects)
- [Hair loss on a GLP-1: how common it is per drug, and why](https://pepvault.app/guides/hair-loss-on-a-glp-1)
- ["Ozempic face": what it is, and where the weight comes from](https://pepvault.app/guides/ozempic-face)
- [Foundayo (orforglipron) vs the shots: the trial numbers side by side](https://pepvault.app/guides/foundayo-vs-the-shots)
- [Is compounded semaglutide or tirzepatide the same as Ozempic or Zepbound?](https://pepvault.app/guides/compounded-glp-1-vs-brand)
- [Why compounded semaglutide and tirzepatide come with B12, glycine or B6, and what it changes](https://pepvault.app/guides/compounded-glp-1-with-b12)
- [Is there a generic Ozempic? Generic semaglutide and Sevmia](https://pepvault.app/guides/generic-semaglutide)
- [How much does a GLP-1 cost in 2026? Zepbound, Wegovy and Medicare prices](https://pepvault.app/guides/how-much-does-a-glp-1-cost)
- [What to eat on a GLP-1: what the trials and the guidelines say](https://pepvault.app/guides/what-to-eat-on-a-glp-1)
- [How much protein per day? The numbers by weight and goal](https://pepvault.app/guides/how-much-protein-per-day)
- [Muscle on a GLP-1: how much of the weight lost is lean mass?](https://pepvault.app/guides/muscle-on-a-glp-1)
- [Intermittent fasting on a GLP-1: what the trials and labels say](https://pepvault.app/guides/intermittent-fasting-on-a-glp-1)
- [Coffee on a GLP-1: can you drink it, and why it can taste different](https://pepvault.app/guides/coffee-on-a-glp-1)
- [Food noise on a GLP-1: what it is and what happens after stopping](https://pepvault.app/guides/food-noise-on-a-glp-1)
- [GLP-1s and menopause: what the trials say about women in midlife](https://pepvault.app/guides/glp-1s-and-menopause)
- [Stopping a GLP-1: what happens to your weight](https://pepvault.app/guides/stopping-a-glp-1)
- [How to keep the weight off after a GLP-1: what each trial tested](https://pepvault.app/guides/keeping-weight-off-after-a-glp-1)
- [Berberine vs metformin vs a GLP-1: what each does to weight and glucose](https://pepvault.app/guides/berberine-vs-metformin-vs-glp-1)
- [Natural GLP-1 alternatives: what the evidence shows for berberine, fiber and supplements](https://pepvault.app/guides/natural-glp-1-alternatives)
- [What is 5-Amino-1MQ? What's been measured](https://pepvault.app/guides/5-amino-1mq-explained)
- [Retatrutide from a lab vial: what independent testing found](https://pepvault.app/guides/retatrutide-lab-vial-tests)
- [Switching from Saxenda to Wegovy: how the change works](https://pepvault.app/guides/saxenda-to-wegovy)
- [Do you stop Ozempic, Wegovy, Mounjaro or Zepbound before surgery?](https://pepvault.app/guides/glp-1-before-surgery)
- [Diarrhea on a GLP-1: how common, and how long it lasts](https://pepvault.app/guides/diarrhea-on-a-glp-1)
- [Dizziness on a GLP-1: dehydration, blood pressure or blood sugar?](https://pepvault.app/guides/dizziness-on-a-glp-1)
- [Heartburn and acid reflux on a GLP-1: the rates, the timing and what helps](https://pepvault.app/guides/heartburn-on-a-glp-1)
- [Does Ozempic or Mounjaro make you tired? Fatigue in the trials](https://pepvault.app/guides/glp-1-fatigue)
- [Can a GLP-1 cause low blood sugar if you do not have diabetes?](https://pepvault.app/guides/glp-1-low-blood-sugar)
- [Is there a medicine for GLP-1 nausea? Tradipitant, so far](https://pepvault.app/guides/tradipitant-for-glp-1-nausea)
- [GLP-1s and mood: depression, anxiety and what the FDA review found](https://pepvault.app/guides/glp-1s-and-mood)
- [Can Ozempic cause vision loss? GLP-1s and NAION, by the numbers](https://pepvault.app/guides/glp-1-and-naion)
- [Are GLP-1s safe long term? What the longest trials show](https://pepvault.app/guides/are-glp-1s-safe-long-term)
- [GLP-1s and the kidneys: what FLOW showed, and the dehydration risk](https://pepvault.app/guides/glp-1s-and-the-kidneys)
- [Can you drink alcohol on Ozempic, Mounjaro or another GLP-1?](https://pepvault.app/guides/alcohol-on-a-glp-1)
- [Do GLP-1s reduce alcohol cravings? What the trials found](https://pepvault.app/guides/glp-1-and-alcohol-cravings)
- [GLP-1s and fatty liver: what the trials measured](https://pepvault.app/guides/glp-1-and-fatty-liver)
- [GLP-1s after a gastric sleeve or bypass: regain, dosing and sleeve vs GLP-1](https://pepvault.app/guides/glp-1-after-bariatric-surgery)
- [Can you drink alcohol on retatrutide?](https://pepvault.app/guides/retatrutide-and-alcohol)
- [Ozempic, Wegovy, Mounjaro or Zepbound not working? Slow responders and plateaus in the trials](https://pepvault.app/guides/glp-1-not-working)
- [Intermittent fasting for weight and fat loss: what the trials measured](https://pepvault.app/guides/intermittent-fasting-weight-loss)
- [Can you take metformin with Ozempic, Mounjaro or another GLP-1?](https://pepvault.app/guides/metformin-with-a-glp-1)
- [GLP-1s and pregnancy: Ozempic, Wegovy, Mounjaro and Zepbound before and during](https://pepvault.app/guides/glp-1s-and-pregnancy)
- [Can you take Ozempic, Mounjaro or another GLP-1 while breastfeeding?](https://pepvault.app/guides/glp-1-while-breastfeeding)
- [Eloralintide, petrelintide and amycretin: the amylin drugs in trials](https://pepvault.app/guides/amylin-drugs-in-trials)
- [Olatorepatide (HS-20094): Regeneron's obesity drug, what is known so far](https://pepvault.app/guides/olatorepatide-explained)
- [Berobenatide (PF-08653944, MET-097i): Pfizer's monthly GLP-1 shot, what is known so far](https://pepvault.app/guides/berobenatide-explained)
- [The GLP-1 pipeline: every drug in phase 2 and 3, and when its trials finish](https://pepvault.app/guides/glp-1-pipeline)
- [Is there a monthly GLP-1 shot? MariTide and berobenatide](https://pepvault.app/guides/monthly-glp-1-shots)
- [Cagrilintide alone: RENEW 1 phase 3 results and what to expect](https://pepvault.app/guides/renew-1-cagrilintide-results)
- [Wegovy HD: is 7.2 mg worth it, and what changes from 2.4 mg](https://pepvault.app/guides/wegovy-hd-7-2-mg)
- [Zenagamtide (amycretin): Novo's GLP-1 and amylin shot and pill, what the trials show](https://pepvault.app/guides/zenagamtide-amycretin)
- [Wegovy and Ozempic price, Medicare and WADA: what changes on January 1, 2027](https://pepvault.app/guides/glp-1-changes-january-2027)
- [Can you take sermorelin with Ozempic, Mounjaro or another GLP-1?](https://pepvault.app/guides/sermorelin-with-a-glp-1)
- [Retatrutide in women: what the studies included](https://pepvault.app/guides/retatrutide-in-women)
- [Peptides for women: what the trials in women show, and after 40](https://pepvault.app/guides/peptides-for-women)
- [Low-dose naltrexone (LDN) for weight loss: what the trials measured](https://pepvault.app/guides/ldn-for-weight-loss)
- [GLP-1s and PCOS: what the trials show, and how they compare with metformin](https://pepvault.app/guides/glp-1-and-pcos)
- [GLP-1s and sleep: insomnia, vivid dreams and the sleep apnea approval](https://pepvault.app/guides/glp-1s-and-sleep)

### Terms on this page

- [Amino acid](https://pepvault.app/glossary/amino-acid)
- [Half-life](https://pepvault.app/glossary/half-life)
- [GLP-1](https://pepvault.app/glossary/glp-1)
- [Glucagon](https://pepvault.app/glossary/glucagon)
- [Placebo](https://pepvault.app/glossary/placebo)
- [Boxed warning](https://pepvault.app/glossary/boxed-warning)
- [Discontinued (Drugs@FDA)](https://pepvault.app/glossary/discontinued)
- [Double-blind](https://pepvault.app/glossary/double-blind)

<!--promo-->

PepVault for iPhone

## Keep your protocol in PepVault

Log every dose, track every vial, and see your protocol come together.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=guide-card-sticky&mt=8)

7 days free on the yearly plan for new subscribers.

[Explore the live demo](https://pepvault.app/login)

<!--/promo-->

PepVault is a research and tracking resource, not medical advice. Ranges are what studies used, never a dose for you. Brand names are trademarks of their owners; PepVault is independent of them.

PepVault is a private research and tracking tool, not medical advice. The information here is reference material from published literature and community use — always verify it and discuss any protocol with a qualified clinician before changing it.

© 2026 PepVault. Our text, data and tools may not be copied, scraped or republished without [permission](https://pepvault.app/terms#content).
